ProCE Banner Activity

New Targeted Therapies and the Evolution of Urothelial Carcinoma Care

Multimedia
Learn how the experts leverage targeted therapies for optimal care of urothelial carcinoma in this on-demand Webcast from a live Webinar.

Released: March 25, 2021

Expiration: March 24, 2022

Share

Faculty

Petros Grivas

Petros Grivas, MD, PhD

Associate Professor
Clinical Director
, Genitourinary Cancers Program
Division of Medical Oncology
Department of Medicine
University of Washington
Associate Member, Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle Cancer Care Alliance
Seattle, Washington

Cora N. Sternberg

Cora N. Sternberg, MD

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Immunomedics

Learning Objectives

  • Plan therapy for patients with urothelial carcinoma and disease progression during or following platinum-containing chemotherapy and/or immune checkpoint inhibitor therapy
  • Describe the unique mechanisms of action of novel targeted therapies for the treatment of advanced urothelial carcinoma
  • Identify patients, through predictive biomarkers, most likely to respond to personalized targeted therapies
  • Discuss ongoing clinical trials investigating targeted systemic therapies in the treatment advanced urothelial carcinoma

Faculty Disclosure

Primary Author

Petros Grivas, MD, PhD

Associate Professor
Clinical Director
, Genitourinary Cancers Program
Division of Medical Oncology
Department of Medicine
University of Washington
Associate Member, Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle Cancer Care Alliance
Seattle, Washington

Petros Grivas, MD, PhD, has disclosed that he has received consulting fees from AstraZeneca, Bayer, Bristol-Myers Squibb, Clovis Oncology, Dyania, Driver, EMD Serono, Exelixis, Foundation Medicine, Genentech/Roche, Genzyme, GlaxoSmithKline, Immunomedics, Janssen, Merck, Mirati, Pfizer, and Seattle Genetics and funds for research support from Bavarian Nordic, Bristol-Myers Squibb, Clovis Oncology, Debiopharm, GlaxoSmithKline, Immunomedics, Kure It Cancer Research, Merck, Mirati Therapeutics, Pfizer, and QED Therapeutics.

Cora N. Sternberg, MD

Cora N. Sternberg, MD, FACP, has disclosed that she has received consulting fees from Astellas, AstraZeneca, Foundation Medicine, Immunomedics, Incyte, MSD, Pfizer, Roche/Genentech, and Sanofi/Genzyme.

Staff Disclosure

Staff

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.

Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant conflicts of interest to report.

Jason J. Everly, PharmD

Jason Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Kiran Mir-Hudgeons, PhD

Clinical Editor

Kiran D. Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.